Allarity Therapeutics Inc

Allarity Therapeutics, Inc. is a clinical-stage precision medicine pharmaceutical company focused on developing anti-cancer therapeutics for patients with unmet medical needs in Denmark and the United States. It uses its proprietary drug response predictor (DRP) technology to create drug-specific companion diagnostics for personalized cancer treatment. Its lead candidate, stenoparib, is a dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) in a Phase 2 trial for advanced and recurrent ovarian cancer. The company is also developing stenoparib with temozolomide, a PARP and WNT inhibitor combined with a DNA-alkylating chemotherapy agent, in a Phase 2 trial for relapsed small cell lung cancer, as well as stenoparib-DRP, a companion diagnostic for patient selection. Allarity Therapeutics, Inc. is headquartered in Tarpon Springs, Florida.

ALLR

Allarity Therapeutics to Present Phase 2 Stenoparib Trial-in-Progress Poster at ESMO Gynaecological Cancers Congress 2026

Allarity Therapeutics will present a Trial-in-Progress poster on its ongoing Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. The poster, presented by Principal Investigator Kathleen N. Moore, outlines the study design and clinical rationale for evaluating stenoparib in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer, building on prior Phase 2 clinical experience that showed durable clinical benefit in heavily pretreated patients. As a Trial-in-Progress presentation, it does not include new clinical data. The poster will be available on the company's website following its presentation on June 18, 2026.

ALLR

GlobeNewswire·92dRead more →